

ASX RELEASE

Scheme update – New Zealand overseas investment consent

Wellington, NZ, 31 January 2024: On 14 December 2023, [Volpara Health Technologies Limited](#) ("Volpara"; ASX:VHT) announced that it had entered into a Scheme Implementation Agreement ("SIA") under which Lunit, Inc. ("Acquirer") conditionally agreed to acquire all of Volpara's shares by means of a scheme of arrangement under New Zealand law (the "Scheme").

The SIA is subject to a number of conditions, including the Acquirer obtaining all consents required under New Zealand's Overseas Investment Act 2005 and Overseas Investment Regulations 2005 to permit the implementation of the Scheme. Those consents have now been obtained and, accordingly, the "OIO Condition" in the SIA has been satisfied.

Authorisation & Additional Information

This announcement was authorised by the CEO & MD of Volpara Health Technologies Limited.

ENDS

For further information please contact:

Corporate enquiries

Teri Thomas, CEO & MD

Volpara Health Technologies

teri.thomas@volparahealth.com

t: +64 4 499 6029

Investor relations

Shareholder Information Line

Toll: 1300 513 794

AU Toll-free: +61 2 9066 4082

NZ Toll-free: +64 9 889 6570

Media enquiries

Clive Mathieson

Cato & Clive

clive@catoandclive.com

t: 61 411 888 425

About Volpara Health Technologies Limited (ASX: VHT)

Volpara Health Technologies makes software to save families from cancer. Volpara helps leading healthcare providers positively impact their patients and families around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, improve and maintain mammogram quality, provide objective mammogram density, and speed up and smooth the arduous reporting necessary for mammography accreditation.

Volpara's focus on customer value means that its AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staff shortages, Volpara's software helps streamline operations and provides key performance insights that support continuous quality improvement.

A Certified B Corporation, Volpara is the preferred partner of leading healthcare institutions around the world. It maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. With a strong sales base in the United States and Australia, Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit www.volparahealth.com

For personal use only